{"id":"gemcitabine-combined-with-docetaxel","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"20-40","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"40-60","effect":"Fatigue"},{"rate":"10-30","effect":"Peripheral neuropathy"},{"rate":"50-80","effect":"Alopecia"},{"rate":"10-20","effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL3039516","moleculeType":"Small molecule","molecularWeight":"527.65"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine is a nucleoside analog that interferes with DNA replication by inhibiting ribonucleotide reductase and being incorporated into DNA, causing chain termination. Docetaxel is a taxane that binds to β-tubulin and stabilizes microtubules, preventing their disassembly and blocking mitosis. The combination exploits complementary mechanisms of action to enhance cytotoxic effects against cancer cells.","oneSentence":"Gemcitabine and docetaxel work synergistically as chemotherapy agents—gemcitabine inhibits ribonucleotide reductase to disrupt DNA synthesis, while docetaxel stabilizes microtubules to prevent cell division—together targeting rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:49.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"},{"name":"Ovarian cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":250},{"nctId":"NCT06632327","phase":"PHASE3","title":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-12-11","conditions":"Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":1100},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT06972615","phase":"PHASE2","title":"Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy","status":"NOT_YET_RECRUITING","sponsor":"BLATAM","startDate":"2026-04-01","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":37},{"nctId":"NCT04577014","phase":"PHASE1, PHASE2","title":"Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-29","conditions":"Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma","enrollment":98},{"nctId":"NCT06592599","phase":"PHASE2","title":"Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-09-03","conditions":"Nasopharyngeal Carcinoma","enrollment":24},{"nctId":"NCT05616624","phase":"PHASE1, PHASE2","title":"ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-04-05","conditions":"Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer","enrollment":31},{"nctId":"NCT03598595","phase":"PHASE1, PHASE2","title":"Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-28","conditions":"Recurrent Osteosarcoma, Refractory Osteosarcoma","enrollment":31},{"nctId":"NCT05634369","phase":"PHASE1, PHASE2","title":"A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-11-14","conditions":"Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed","enrollment":50},{"nctId":"NCT07351565","phase":"PHASE1","title":"Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chang Chen","startDate":"2026-01-10","conditions":"Non-Small Cell Lung Cancer","enrollment":22},{"nctId":"NCT06976190","phase":"PHASE3","title":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2025-05-06","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":446},{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT07330596","phase":"PHASE2","title":"QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC","status":"RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-10-30","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":96},{"nctId":"NCT05481645","phase":"PHASE2","title":"Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-08-26","conditions":"Advanced Endometrial Cancer, Sarcoma of Uterus","enrollment":71},{"nctId":"NCT00565851","phase":"PHASE3","title":"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-06","conditions":"Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":1052},{"nctId":"NCT03449901","phase":"PHASE2","title":"ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-05-09","conditions":"Soft Tissue Sarcoma","enrollment":98},{"nctId":"NCT05516914","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2022-09-01","conditions":"Malignant Tumors","enrollment":490},{"nctId":"NCT06230055","phase":"PHASE4","title":"Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-01-05","conditions":"HER2-negative Breast Cancer, Leptomeningeal Metastasis","enrollment":37},{"nctId":"NCT03137771","phase":"PHASE2","title":"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2017-04-07","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer","enrollment":218},{"nctId":"NCT02495896","phase":"PHASE1","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2015-09-03","conditions":"Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma","enrollment":61},{"nctId":"NCT06929286","phase":"PHASE3","title":"A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-04-11","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":125},{"nctId":"NCT06865339","phase":"PHASE2","title":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nitin Ohri","startDate":"2025-08-07","conditions":"NSCLC, Locally Advanced","enrollment":76},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT06632951","phase":"PHASE2","title":"Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2025-01-20","conditions":"Urothelial Carcinoma","enrollment":150},{"nctId":"NCT04306900","phase":"PHASE1","title":"TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers","status":"COMPLETED","sponsor":"Trishula Therapeutics, Inc.","startDate":"2020-03-30","conditions":"Solid Tumor, Adult","enrollment":185},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT06902272","phase":"PHASE2","title":"ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-06-11","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07050043","phase":"PHASE3","title":"Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC","status":"RECRUITING","sponsor":"Dr Arvindran A/L Alaga","startDate":"2025-05-19","conditions":"NSCLC (Non-small Cell Lung Carcinoma), First Line Therapy, Locally Advanced/Metastatic NSCLC","enrollment":123},{"nctId":"NCT03884556","phase":"PHASE1","title":"TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers","status":"COMPLETED","sponsor":"Trishula Therapeutics, Inc.","startDate":"2019-04-10","conditions":"Solid Tumor, Lymphoma","enrollment":56},{"nctId":"NCT06311981","phase":"PHASE2","title":"Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-08-08","conditions":"Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy","enrollment":29},{"nctId":"NCT05096663","phase":"PHASE2, PHASE3","title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2022-03-15","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":82},{"nctId":"NCT06003075","phase":"PHASE2","title":"Induction Chemo-Nivo in Unresectable Stage III NSCLC","status":"TERMINATED","sponsor":"Ralph G Zinner","startDate":"2023-12-13","conditions":"Lung Cancer, Nonsmall Cell, Lung Cancer Stage III","enrollment":1},{"nctId":"NCT06935409","phase":"PHASE3","title":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-04-30","conditions":"Osteosarcoma","enrollment":117},{"nctId":"NCT04553692","phase":"PHASE1","title":"Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers","status":"TERMINATED","sponsor":"IGM Biosciences, Inc.","startDate":"2020-09-23","conditions":"Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma","enrollment":272},{"nctId":"NCT06892431","phase":"PHASE2","title":"JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-04-01","conditions":"Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy","enrollment":150},{"nctId":"NCT00544414","phase":"PHASE2","title":"Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2000-06-07","conditions":"Head and Neck Cancer","enrollment":31},{"nctId":"NCT01957735","phase":"PHASE1","title":"BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors","status":"COMPLETED","sponsor":"BPGbio","startDate":"2013-10","conditions":"Metastatic Cancer, Cancer, Solid Tumor","enrollment":97},{"nctId":"NCT05431270","phase":"PHASE1, PHASE2","title":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2022-08-11","conditions":"Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":40},{"nctId":"NCT02723955","phase":"PHASE1","title":"Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-23","conditions":"Neoplasms","enrollment":829},{"nctId":"NCT01905150","phase":"PHASE2","title":"Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer","status":"COMPLETED","sponsor":"Bruckner Oncology","startDate":"2014-08-13","conditions":"Pancreatic Cancer","enrollment":34},{"nctId":"NCT06719479","phase":"PHASE2, PHASE3","title":"A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).","status":"NOT_YET_RECRUITING","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","startDate":"2025-01-01","conditions":"NPC, HNSCC, Recurrence","enrollment":60},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT06678763","phase":"","title":"Combined CRS With HIPEC in Women With Inadvertently Morcellated uLMS","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-01-01","conditions":"Uterine Leiomyosarcoma","enrollment":19},{"nctId":"NCT03839823","phase":"PHASE2","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-25","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT05517135","phase":"","title":"tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-11-17","conditions":"Nasopharyngeal Carcinoma","enrollment":1000},{"nctId":"NCT05684731","phase":"PHASE1","title":"Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-02-01","conditions":"Ovarian Cancer","enrollment":30},{"nctId":"NCT04931420","phase":"PHASE2","title":"Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-05-19","conditions":"Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma","enrollment":""},{"nctId":"NCT06370871","phase":"PHASE3","title":"Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2024-06-27","conditions":"Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Myxofibrosarcoma (MFS)","enrollment":""},{"nctId":"NCT06467500","phase":"PHASE2","title":"A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy","status":"RECRUITING","sponsor":"Xin-Hua Xu","startDate":"2024-03-01","conditions":"Non-small Cell Lung Cancer","enrollment":48},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT06421298","phase":"PHASE2","title":"A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.","status":"RECRUITING","sponsor":"Jinghui Wang","startDate":"2024-05-17","conditions":"Lung Cancer","enrollment":30},{"nctId":"NCT03887130","phase":"PHASE2","title":"Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2007-03-27","conditions":"Breast Cancer","enrollment":152},{"nctId":"NCT06156878","phase":"PHASE2","title":"PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":41},{"nctId":"NCT03083808","phase":"PHASE2","title":"Phase II Trial of Continuation Therapy in Advanced NSCLC","status":"COMPLETED","sponsor":"Greg Durm, MD","startDate":"2017-03-20","conditions":"Non-Small-Cell Lung Cancer","enrollment":35},{"nctId":"NCT03840915","phase":"PHASE1, PHASE2","title":"M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-04-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":70},{"nctId":"NCT02324543","phase":"PHASE1, PHASE2","title":"Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-02","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":47},{"nctId":"NCT05116891","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cantargia AB","startDate":"2021-09-22","conditions":"Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT00003810","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-08-11","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT03386721","phase":"PHASE2","title":"Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-02-19","conditions":"Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers","enrollment":256},{"nctId":"NCT05549466","phase":"PHASE2","title":"Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-10-08","conditions":"Nasopharyngeal Carcinoma","enrollment":84},{"nctId":"NCT00312728","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer, Brain Neoplasms","enrollment":115},{"nctId":"NCT02511132","phase":"PHASE2","title":"A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma","status":"COMPLETED","sponsor":"Gradalis, Inc.","startDate":"2016-02-10","conditions":"Ewing's Sarcoma","enrollment":22},{"nctId":"NCT01879085","phase":"PHASE1, PHASE2","title":"Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma","status":"COMPLETED","sponsor":"Melissa Burgess, MD","startDate":"2013-09-24","conditions":"Sarcoma","enrollment":37},{"nctId":"NCT02659020","phase":"PHASE1, PHASE2","title":"A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03-01","conditions":"Soft Tissue Sarcoma","enrollment":310},{"nctId":"NCT05320874","phase":"PHASE1","title":"A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.","status":"NOT_YET_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-04","conditions":"Advanced Solid Tumor","enrollment":232},{"nctId":"NCT04508816","phase":"PHASE2","title":"Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy","status":"COMPLETED","sponsor":"Fudan University","startDate":"2016-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":45},{"nctId":"NCT05173142","phase":"PHASE1, PHASE2","title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Hutchison Medipharma Limited","startDate":"2022-01-22","conditions":"Solid Tumor","enrollment":141},{"nctId":"NCT05116800","phase":"PHASE2","title":"Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma","status":"WITHDRAWN","sponsor":"Brown University","startDate":"2022-03-01","conditions":"Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma","enrollment":""},{"nctId":"NCT04906876","phase":"PHASE2","title":"A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas","status":"WITHDRAWN","sponsor":"Brown University","startDate":"2021-09","conditions":"Sarcoma, Soft Tissue Sarcoma, Metastatic Sarcoma","enrollment":""},{"nctId":"NCT01459614","phase":"PHASE2","title":"Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2011-11","conditions":"Pancreatic Cancer","enrollment":44},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT04846634","phase":"PHASE2","title":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-08","conditions":"Resectable Locally Advanced Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT04772287","phase":"PHASE3","title":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-03-31","conditions":"Non Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT00227721","phase":"PHASE2","title":"Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer","status":"COMPLETED","sponsor":"Robert Morris","startDate":"2004-02","conditions":"Ovarian Cancer, Peritoneal Cavity Cancer","enrollment":30},{"nctId":"NCT03758677","phase":"PHASE2","title":"Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2020-08-01","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT01862328","phase":"PHASE1","title":"Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2013-06-10","conditions":"Solid Tumors","enrollment":64},{"nctId":"NCT02117024","phase":"PHASE2","title":"A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Heat Biologics","startDate":"2014-07","conditions":"Non Small Cell Lung Cancer","enrollment":66},{"nctId":"NCT03121833","phase":"PHASE2","title":"Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2017-05-01","conditions":"Soft Tissue Sarcoma, Adult, Stage IIB","enrollment":52},{"nctId":"NCT01951157","phase":"PHASE2","title":"A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients","status":"COMPLETED","sponsor":"PharmaMar","startDate":"2013-09-11","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":69},{"nctId":"NCT01574716","phase":"PHASE2","title":"Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation","status":"COMPLETED","sponsor":"Morphotek","startDate":"2012-08-07","conditions":"Metastatic Soft Tissue Sarcoma","enrollment":209},{"nctId":"NCT02341456","phase":"PHASE1","title":"Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-16","conditions":"Advanced Solid Tumours","enrollment":19},{"nctId":"NCT00248560","phase":"PHASE2","title":"Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2005-01","conditions":"Head and Neck Cancer","enrollment":36},{"nctId":"NCT01284335","phase":"PHASE1","title":"A Safety Study in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2008-07","conditions":"Advanced Solid Tumors","enrollment":234},{"nctId":"NCT03723343","phase":"","title":"GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-10-18","conditions":"Advanced Nasopharyngeal Carcinoma","enrollment":146},{"nctId":"NCT01106872","phase":"PHASE1","title":"Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas","status":"COMPLETED","sponsor":"Mohammed M Milhem","startDate":"2010-09","conditions":"Sarcoma, Soft Tissue Sarcoma, Locally Advanced Sarcoma","enrollment":47},{"nctId":"NCT03604965","phase":"PHASE3","title":"GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-07-21","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":204},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT03489616","phase":"NA","title":"Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2018-01-15","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT00790816","phase":"PHASE1","title":"Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10","conditions":"Neoplasms, Breast","enrollment":500},{"nctId":"NCT00093795","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2004-10","conditions":"Breast Cancer","enrollment":4894},{"nctId":"NCT01418001","phase":"PHASE1, PHASE2","title":"Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-08","conditions":"Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor","enrollment":5},{"nctId":"NCT02249702","phase":"PHASE2","title":"Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2010-04","conditions":"Leiomyosarcoma","enrollment":168},{"nctId":"NCT02777788","phase":"PHASE2, PHASE3","title":"Curative Study of Chinese Traditional Medicine to Treat Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2014-09","conditions":"Cancer","enrollment":120},{"nctId":"NCT00833859","phase":"PHASE2","title":"Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2009-03","conditions":"Pancreatic Neoplasms","enrollment":2},{"nctId":"NCT02455843","phase":"PHASE3","title":"Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2015-05","conditions":"Non Small Cell Lung Cancer","enrollment":275},{"nctId":"NCT00031629","phase":"PHASE2","title":"Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2005-01","conditions":"Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma","enrollment":51}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gemcitabine combined with docetaxel","genericName":"Gemcitabine combined with docetaxel","companyName":"Hansoh BioMedical R&D Company","companyId":"hansoh-biomedical-r-d-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine and docetaxel work synergistically as chemotherapy agents—gemcitabine inhibits ribonucleotide reductase to disrupt DNA synthesis, while docetaxel stabilizes microtubules to prevent cell division—together targeting rapidly dividing cancer cells. Used for Non-small cell lung cancer, Breast cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}